1218791-44-6 Usage
General Description
N-Ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine is a chemical compound with the molecular formula C13H21BN4O2. It is a pyrimidine derivative with an ethyl group and a boron-containing ring structure. N-Ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine is used in organic synthesis as a reagent for the preparation of various pharmaceuticals and agrochemicals. It is also utilized in the development of new materials and in research for its potential biological activity. N-Ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine plays a significant role in the field of medicinal and chemical industries due to its unique structural and functional properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1218791-44-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,8,7,9 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1218791-44:
(9*1)+(8*2)+(7*1)+(6*8)+(5*7)+(4*9)+(3*1)+(2*4)+(1*4)=166
166 % 10 = 6
So 1218791-44-6 is a valid CAS Registry Number.
1218791-44-6Relevant articles and documents
1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
-
Page/Page column 163, (2010/12/29)
The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.